On November 7, 2025, MetaVia Inc. reported encouraging results from its Phase 2a trial of vanoglipel, showing significant improvements in glucose control and liver health after 16 weeks of treatment. The trial revealed a mean HbA1c decrease of up to -0.66%, highlighting vanoglipel's potential as a treatment for metabolic dysfunction-associated steatohepatitis.